NASDAQ: BNOX - Bionomics Limited

Rentabilidade por seis meses: -4.96%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Bionomics Limited

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Bionomics Limited

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

mais detalhes
It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2021-12-16
ISIN US09063M2052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://www.bionomics.com.au
Цена ао 5.01
Alteração de preço por dia: 0% (5.01)
Alteração de preço por semana: 0% (5.01)
Alteração de preço por mês: 0% (5.01)
Alteração de preço em 3 meses: +24.32% (4.03)
Mudança de preço em seis meses: -4.96% (5.2716)
Mudança de preço por ano: +401% (1)
Mudança de preço em 3 anos: -41.27% (8.53)
Mudança de preço desde o início do ano: +46.06% (3.43)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 4290.29 1
P/BV 4.91 3
P/E 0 0
EV/EBITDA -7.47 0
Total: 3.13

Eficiência

Nome Significado Nota
ROA, % -66284.99 0
ROE, % -117366.73 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0278 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -98.45 0
Rentabilidade Ebitda, % 272.62 10
Rentabilidade EPS, % 74771112.12 10
Total: 8
Mais detalhes

Instituições Volume Compartilhar, %
Lynx1 Capital Management Lp 824305 10.1
Point72 Asset Management, L.P. 331000 4.06
Morgan Stanley 94967 1.16
Two Sigma Investments, LP 31272 0.38
XTX Topco Ltd 11834 0.15
Tower Research Capital LLC (TRC) 1606 0.02
Rhumbline Advisers 505 0.01
UBS Group AG 329 0
Aspire Private Capital, LLC 200 0



Supervisor Cargo Pagamento Ano de nascimento
Dr. Spyridon Papapetropoulos M.D., Ph.D. CEO, President & Director 510.37k 1973 (52 ano)
Mr. Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer N/A 1963 (62 ano)
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations N/A
Ms. Elizabeth Doolin Senior Vice President of Clinical Development 1965 (60 anos)
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer 1955 (70 anos)

Endereço: Australia, Eastwood, 200 Greenhill Road - abrir no Google Maps, abrir mapas Yandex
Site: https://www.bionomics.com.au